Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in October 2006 on request of the sponsor.
On 30 June 2003, orphan designation (EU/3/03/146) was granted by the European Commission to Chiron B. V., the Netherlands, for aldesleukin (inhalation use) for the treatment of renal cell carcinoma.
The sponsorship was transferred to Chiron Corporation Limited, United Kingdom, in November 2005.
Treatment of renal-cell carcinoma
|Orphan designation status||
|EU designation number||
|Date of designation||
Chiron Corporation Limited
7 Cowley Business Park, High Street
Telephone: +44 20 85 80 40 00
Telefax: +44 20 85 80 40 97
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: